Nexalin Technology, INC 10-Q quarterly reports

Nexalin Technology, Inc. reported increased operating losses and a going concern warning, alongside receiving a staff delisting determination from Nasdaq, despite advancing its clinical trials and acquiring PONM, Inc.

Nexalin Technology reports a net loss of $2.1 million for Q1 2026 while advancing clinical trials for its neurostimulation devices.

Nexalin Technology reports a narrower net loss in Q3 2025, driven by reduced operating expenses, while securing a significant FDA Q-Submission acceptance for its Gen-2 SYNC system targeting Alzheimer's and dementia.

Nexalin Technology, Inc. reported a significant increase in net loss for Q2 2025 and the first half of 2025, driven by higher operating expenses, despite revenue growth and a successful capital raise.

Nexalin Technology's Q1 2025 results show a decrease in revenue compared to Q1 2024, coupled with increased operating expenses, particularly in research and development.

Nexalin Technology's Q3 2024 report reveals increased revenue but ongoing losses, alongside efforts to navigate regulatory hurdles and maintain Nasdaq listing compliance.

Nexalin Technology's Q2 2024 report details financial results, ongoing regulatory efforts, and strategic developments in the neurostimulation device market.

Nexalin Technology's first quarter 2024 results show a significant increase in revenue driven by international device sales, alongside ongoing efforts to gain regulatory approvals for their neurostimulation devices.